[Patient-related rejection of nasal IPPV therapy. Patients, reasons, follow-up].
We retrospectively analysed the course of 33 patients who had rejected nasal IPPV-therapy (1988 to February 1996). The death-rate was higher (48%) compared to nasal IPPV patients in the same time (18%). The patients were divided in 3 main diagnostic groups (COPD, restrictive thoracic wall, neuromuscle disease). We observed the highest death-rate in COPD patients (66%) and the lowest death-rate in the group with scoliosis or chest wall disease (23%). This is the same result tendencially as in patients with nasal IPPV (mortality-rate COPD 66%, restrictive chest wall 6%).